JP2005506992A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506992A5
JP2005506992A5 JP2003537557A JP2003537557A JP2005506992A5 JP 2005506992 A5 JP2005506992 A5 JP 2005506992A5 JP 2003537557 A JP2003537557 A JP 2003537557A JP 2003537557 A JP2003537557 A JP 2003537557A JP 2005506992 A5 JP2005506992 A5 JP 2005506992A5
Authority
JP
Japan
Prior art keywords
composition
acid
active compound
pharmaceutically acceptable
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003537557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506992A (ja
JP4850390B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033300 external-priority patent/WO2003034988A2/en
Publication of JP2005506992A publication Critical patent/JP2005506992A/ja
Publication of JP2005506992A5 publication Critical patent/JP2005506992A5/ja
Application granted granted Critical
Publication of JP4850390B2 publication Critical patent/JP4850390B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003537557A 2001-10-19 2002-10-18 薬理学的に活性な化合物の制御送達のための注射用組成物 Expired - Lifetime JP4850390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34362501P 2001-10-19 2001-10-19
US60/343,625 2001-10-19
PCT/US2002/033300 WO2003034988A2 (en) 2001-10-19 2002-10-18 Injectable compositions for the controlled delivery of pharmacologically active compound

Publications (3)

Publication Number Publication Date
JP2005506992A JP2005506992A (ja) 2005-03-10
JP2005506992A5 true JP2005506992A5 (enExample) 2006-01-05
JP4850390B2 JP4850390B2 (ja) 2012-01-11

Family

ID=23346878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537557A Expired - Lifetime JP4850390B2 (ja) 2001-10-19 2002-10-18 薬理学的に活性な化合物の制御送達のための注射用組成物

Country Status (16)

Country Link
US (4) US6887487B2 (enExample)
EP (1) EP1446103B1 (enExample)
JP (1) JP4850390B2 (enExample)
CN (2) CN101785861B (enExample)
AU (1) AU2002335077B2 (enExample)
BG (1) BG108634A (enExample)
BR (1) BRPI0213425B8 (enExample)
CA (1) CA2463896C (enExample)
ES (1) ES2561108T3 (enExample)
IL (1) IL160282A (enExample)
MX (1) MXPA04003608A (enExample)
NZ (1) NZ531460A (enExample)
PL (1) PL211116B1 (enExample)
RU (1) RU2292871C2 (enExample)
WO (1) WO2003034988A2 (enExample)
ZA (1) ZA200401076B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887487B2 (en) * 2001-10-19 2005-05-03 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7854943B2 (en) 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
EP1804771A2 (en) * 2004-10-28 2007-07-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2007016153A2 (en) * 2005-07-28 2007-02-08 Eli Lilly And Company Tilmicosin formulation
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US7973022B2 (en) * 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US20090239891A1 (en) * 2006-03-01 2009-09-24 Shukla Atul J Sustained Release Dosage Forms of Analgesic Medications
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090005326A1 (en) * 2007-06-26 2009-01-01 Idexx Laboratories, Inc. Single dose roxithromycin
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
USRE46397E1 (en) 2007-11-07 2017-05-09 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
CN101496811B (zh) * 2008-12-24 2011-03-16 天津瑞普生物技术股份有限公司 一种可溶且稳定的替米考星组合物
CN101690713B (zh) * 2009-09-28 2011-12-28 普莱柯生物工程股份有限公司 一种喹诺酮注射液的制备方法
US20110177157A1 (en) * 2010-01-19 2011-07-21 Idexx Laboratories, Inc. Compositions for Controlled Delivery of Pharmaceutically Active Compounds
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PT3116475T (pt) 2014-03-13 2020-12-15 Neuroderm Ltd Composições de inibidores de dopa-descarboxilase
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
CN108042491B (zh) * 2018-01-23 2021-02-09 山东迅达康兽药有限公司 一种替米考星纳米乳及其制备方法
US20220202835A1 (en) * 2019-03-01 2022-06-30 Boehringer Ingelheim Animal Health USA Inc. Injectable clorsulon compositions, methods and uses thereof
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN113730340A (zh) * 2021-09-17 2021-12-03 中国药科大学 一种注射用脂肪酸缓释组合物及其制备方法和应用
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB674784A (en) * 1949-05-25 1952-07-02 Chimiotherapie Lab Franc Penicillin preparations for injection
GB731933A (en) * 1951-04-28 1955-06-15 Fougera And Company E Liquid preparations of therapeutically active substances for sub-cutaneous or intramuscular injection
US4259331A (en) * 1979-04-16 1981-03-31 Pfizer Inc. Oxytetracycline compositions
US4298375A (en) 1979-10-01 1981-11-03 Monsanto Company 2-Substituted-5-phenyl-4-thiazolecarboxylic acids and their derivatives as safening agents
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
DE3248328A1 (de) * 1982-12-28 1984-06-28 Bayer Ag, 5090 Leverkusen Schwerloesliche salze von aminoglykosiden sowie diese enthaltende formulierungen mit verzoegerter wirkstoff-freigabe
GB8725427D0 (en) * 1987-10-30 1987-12-02 Lilly Industries Ltd Somatotropin formulations
JPH027314A (ja) 1988-06-27 1990-01-11 Asahi Denso Kk スイッチ
JPH02115118A (ja) * 1988-10-24 1990-04-27 Wakunaga Pharmaceut Co Ltd 注射剤
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
RU2097025C1 (ru) * 1990-11-06 1997-11-27 Ниппон Синяку Компани, Лимитед Лиофилизированный препарат жировой эмульсии и способ его получения
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
NZ250465A (en) * 1992-12-21 1995-10-26 Lilly Co Eli Bactericidal composition; contains macrolide antibiotic, use for treating aquatic species
US6110905A (en) 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
JP3277735B2 (ja) * 1994-12-07 2002-04-22 富士レビオ株式会社 ナフトエ酸誘導体の吸収促進組成物
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6310053B1 (en) 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5723447A (en) 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
CA2263411A1 (en) * 1996-08-12 1998-02-19 Eyal S. Ron Composition for pharmaceutical applications
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
TR199902748T2 (xx) * 1997-05-06 2000-05-22 Norbrook Laboratories Limited Uzun s�re etkili antimikrobik maddelerle ilgili geli�meler
JPH11171794A (ja) * 1997-12-04 1999-06-29 Shoji Awazu 動脈注射製剤
TW565452B (en) 1998-03-02 2003-12-11 Lilly Co Eli A pharmaceutical composition for use in inhibiting swine infertility and respiratory syndrome virus (SIRSV) proliferation in swine in need of treatment
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US6328961B1 (en) 1998-08-20 2001-12-11 Bristol-Myers Squibb Company Tyrissamycin antibiotic
US6174540B1 (en) * 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US6887487B2 (en) 2001-10-19 2005-05-03 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds

Similar Documents

Publication Publication Date Title
JP2005506992A5 (enExample)
RU2004115103A (ru) Инъецируемые композиции для контролируемоей доставки фармакологически активного соединения
CN1205921C (zh) 含有氢化蓖麻油的长效注射制剂
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
CN104797252B (zh) 减轻噪音厌恶的兽医方法
RU2010123282A (ru) Твердая лекарственная форма с быстрым высвобождением активного вещества, ее получение и применение
CA2522009A1 (en) Methods for the controlled delivery of pharmacologically active compounds
US12350281B2 (en) Long-acting injectable formulations and use thereof
JP2007503433A5 (enExample)
EP3082762B1 (en) Long-acting ketoprofen compositions
JP2006523723A5 (enExample)
CN1248165A (zh) 供局部应用的尼美舒利凝胶体系
PT1811995E (pt) Composição veterinária transmucosa compreendendo detomidina
ME00483B (me) Parenteralni sastav paracetamola
ES2204958T3 (es) Compuesto de oxitetraciclina de largo efecto.
JP2002509154A5 (enExample)
WO2018070940A1 (en) An injectable composition for localized controlled and sustained delivery system
JP2007509949A5 (enExample)
KR101352867B1 (ko) 동물용 복합항생제 조성물
JP2008504272A5 (enExample)
CN119816308A (zh) 化学去角方法
WO2011074931A2 (es) Formulación farmacéutica parenteral en suspensión, de liberación sostenida, en dosis baja y ultra baja, en terapia hormonal en el síndrome climatérico
JPH0446116A (ja) マイクロスフィアの製造方法
BRPI0714053A2 (pt) composição farmacêutica contendo bicalutamida e um método para seu uso
WO2004047803A1 (fr) Injection de medicament pour animaux renfermant du closantel ou du sodium de closantel